BacTRL-spike Uses, Dosage, Side Effects and more
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine.
| Trade Name | BacTRL-spike |
| Generic | BacTRL-spike |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
